LeMaistre C Frederick, Farnia Stephanie H
Sarah Cannon, Nashville, Tennessee.
National Marrow Donor Program, Minneapolis, Minnesota.
Biol Blood Marrow Transplant. 2015 Aug;21(8):1367-72. doi: 10.1016/j.bbmt.2015.04.014. Epub 2015 Apr 16.
Bundled payments for hematopoietic cell transplantation (HCT) have long been accepted by both commercial health insurance providers and transplant centers, effectively outpacing the use of this payment model elsewhere in health care. As with the rest of health care, interest in payment and health delivery reform has created demand for transplant providers to address value by incorporating quality metrics and strategic changes in network design The complexity of evaluating performance in HCT complicates the goal of rewarding providers for better performance and penalizing poor results. We provide an introduction to value-based purchasing and address potential considerations in the adoption of incentives to improve quality of care in HCT.
造血细胞移植(HCT)的捆绑支付长期以来已被商业健康保险提供商和移植中心所接受,实际上超过了这种支付模式在医疗保健其他领域的使用。与医疗保健的其他领域一样,对支付和医疗服务改革的关注促使移植服务提供商通过纳入质量指标和网络设计的战略变革来实现价值。评估HCT表现的复杂性使奖励表现更好的服务提供商和惩罚不佳结果的目标变得复杂。我们介绍了基于价值的采购,并讨论了在采用激励措施以提高HCT护理质量时的潜在考虑因素。